Study Title: Open Label Study of Human Corticotropin-Releasing Factor (hCRF)
Category: Cancer, General
Currently accepting participants?
Not at this time.
Principal Investigator: Lynne Taylor MD
Study Coordinator: Gail Chumbley
Phone: 206-223-6835
Email: gchumbley@benaroyaresearch.org
What is the Open Label Study of Human Corticotropin-Releasing Factor (hCRF) study?
Study medication will be provided until hCRF becomes commercially available in the US. The study requires visits every 4 weeks.
Who can participate?
Participation in and completion of stipulated final follow-up periods for study NTI0302 or NTI0303.
Study Summary:
This is an open-label, extended use study of hCRF for all patients who participate in and complete one of the following trials: NTI0302 or NTI0303.
Detailed Study Description:
Study Design: Interventional
Phase of Study: n/a
Study Type: Expanded Access
Condition or Study Focus: Peritumoral Brain Edema
Intervention Type: Drug
Intervention Name: Xerecept: Human Corticotropin-Releasing Factor--hCRF
Gender: Male and Female
Age group: Expanded Access
Sponsor: Celtic Pharma
Other studies in this category include:
Studies currently accepting study participants:
Studies currently not accepting study participants:
- A Randomized Phase III Trial of Concurrent Accelerated Radiation and Cisplatin Versus Concurrent Accelerated Radiation, Cisplatin, and Cetuximab (C225) Followed by Surgery for Selected Patients for Stage III and IV Head and Neck Carcinomas
- AMC045: HIV-Associated Anal Cancer
- Investigating Proteomic Biomarkers of Radiation Therapy Outcome: A Pilot Study
- Investigational drug vs. Placebo for Patients with Renal Cell Carcinoma (Kidney Cancer) at High Risk of Recurrence after Surgery
- Kidney Cancer (Renal Cell Carcinoma): Study Comparing Bevacizumab + Temsirolimus Vs Bevacizumab + Interferon-Alfa In Advanced Renal Cell Carcinoma Subjects (INTORACT)
- Liver Cancer (Hepatocellular Carcinoma): Sorafenib vs Placebo as Adjuvant Treatment
- Liver Cancer (Hepatocellular Carcinoma): Study Of Sunitinib Malate Versus Sorafenib In Patients With Inoperable (Advanced or Metastatic) Liver Cancer
- Liver Cancer (Hepatocellular Carcinoma): TACE for Intermediate Stage
- MK0646 for Patients with Advanced Cancer
- Newly diagnosed, untreated ovarian or peritoneal cancer (GOG 0218)
- Radiation Therapy and Either Capecitabine or Fluorouracil With or Without Oxaliplatin Before Surgery in Treating Patients With Resectable Rectal Cancer
- Sorafenib v. Sunitinib v. Placebo for High Risk Renal Cell Carcinoma Patients
- Trial of FOLFOX with or without cetuximab for colon cancer
- Use of Human Corticotropin-Releasing Factor (hCRF) to Control Brain Swelling (edema) in Brain Tumor Patients
- Weekly IV of Hymcamtin in Combination with Carboplatin as Second Line Therapy in Potentially Platinum-Sensitive Reaplased Ovarian Cancer